| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:15635150 | IVR | 100 mg/kg/day | 100 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 300 mg/kg/day | 300 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:28616630 | IVTH | 0.000000000001 - 0.0001 M | 0.0000005 - 0.000005 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:31388671 | IVTH | 0.000001 M | - | No significant effects observed | - |
| PMID:33254397 | IVR | 5 mg/kg/day | 5 mg/kg/day | Causes inflammation | Immunological endocrine-mediated perturbations |
| PMID:33582643 | IVTH | 0.000001 - 0.000025 M | 0.000001 - 0.000025 M | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations |
| IVTH | 0.00000001 - 0.000001 M | 0.00000001 - 0.000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:35101577 | IVTH | 0.00003 M | 0.00003 M | Altered adipocyte morphology | Metabolic endocrine-mediated perturbations |
| IVTH | 0.00003 M | 0.00003 M | Altered adipogenesis | Metabolic endocrine-mediated perturbations | |
| PMID:37992829 | IVR | 2 mg/kg/day | 2 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 1 - 2 mg/kg/day | 1 - 2 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Increased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Increased gonadotropin-releasing hormone (GnRH) levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Accelerated onset of puberty | Reproductive endocrine-mediated perturbations | |
| PMID:38128231 | IVTH | 0.0001 M | 0.0001 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations |
| PMID:38159341 | IVR | 1 - 2 mg/kg/day | 1 - 2 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 1 - 2 mg/kg/day | 1 - 2 mg/kg/day | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/kg/day | 1 - 5 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/kg/day | 1 - 5 mg/kg/day | Induce apoptosis in testis | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.